EUVIMEDEUVIMED entdecken
Crossref

Unequal Utilization of Overactive Bladder Treatment: The Role of Socioeconomic and Insurance Disparities

Omer Anis, Tyler Trump, Jacob M Knorr, Howard B Goldman

Neurourology and Urodynamics · 2026

DOI: 10.1002/nau.70343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurourology and Urodynamics, 2026. Verfasst von Omer Anis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Healthcare Disparities, Insurance, Health, Insurance Coverage. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the association between neighborhood‐level socioeconomic disadvantage (SED) and insurance type with pharmacologic and procedural treatment patterns in the management of overactive bladder (OAB).

Methods

We conducted a retrospective cohort study of patients diagnosed with OAB at a tertiary academic medical center between 2011 and 2023. Variables included receipt of pharmacotherapy, and minimally invasive therapy (MIT), corresponding to guideline‐defined procedural interventions for OAB, such as sacral neuromodulation (SNM), posterior tibial nerve stimulation (PTNS), and intravesical botulinum toxin (BTX). Neighborhood‐level SED was measured using the area deprivation index (ADI), with patients stratified by national ADI quartile. Higher ADI scores indicate greater SED. Insurance type was recorded.

Results

Among 6786 patients included in the study, higher ADI (greater SED) was associated with increased anticholinergic use and decreased β3‐agonist use ( p < 0.0001). Privately insured patients were less likely to receive therapy than Medicare patients, while Medicare patients experienced the longest delay to MIT (93.6 vs. 89.9 vs. 73.0 months, respectively; p = 0.002). On multivariable analysis, ADI and insurance status independently predicted OAB treatment. Higher rates of BTX were observed among Medicare patients compared with Medicaid and private insurance (17.8% vs. 11.9% vs. 10.4%, p < 0.0001), while lower rates of SNM were observed among Black patients (5.9% vs. 11.4%, p < 0.0001).

Conclusions

Socioeconomic and insurance disparities influence pharmacologic treatment of OAB, while procedural disparities are more strongly associated with insurance status and race. Using ADI as a validated measure of neighborhood‐level SED, we found that patients from more disadvantaged areas were more likely to receive anticholinergic therapy and less likely to be prescribed β3‐agonists.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder, OveractiveHealthcare DisparitiesInsurance, HealthInsurance CoverageHumansFemaleRetrospective StudiesMaleSocioeconomic Disparities in HealthAgedMiddle AgedUnited StatesCholinergic AntagonistsMedicareSocioeconomic FactorsBotulinum Toxins

Stichwörter der Autor:innen

intravesical botoxoveractive bladdersacral neuromodulationsocioeconomic disadvantagetreatment trends

Substanzen

Cholinergic AntagonistsBotulinum Toxins

Autor:innen und Institutionen

  • Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Zitieren

APA

Anis, O., Trump, T., Knorr, J. M., & Goldman, H. B. (2026). Unequal Utilization of Overactive Bladder Treatment: The Role of Socioeconomic and Insurance Disparities. Neurourology and Urodynamics. https://doi.org/10.1002/nau.70343

Vancouver

Anis O, Trump T, Knorr JM, Goldman HB. Unequal Utilization of Overactive Bladder Treatment: The Role of Socioeconomic and Insurance Disparities. Neurourology and Urodynamics. 2026. doi:10.1002/nau.70343

BibTeX
@article{Anis2026,
  author = {Anis, Omer and Trump, Tyler and Knorr, Jacob M and Goldman, Howard B},
  title = {Unequal Utilization of Overactive Bladder Treatment: The Role of Socioeconomic and Insurance Disparities},
  journal = {Neurourology and Urodynamics},
  year = {2026},
  doi = {10.1002/nau.70343}
}
Kostenlos starten →